These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 11817288

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
    Aktaş Z, Gönüllü N, Salcioğlu M, Bal C, Anğ O.
    Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of moxifloxacin against recent community-acquired respiratory tract pathogens isolated in France: a national survey.
    Decousser JW, Allouch PY, Courvalin P, Leclercq R, Study Group.
    Int J Antimicrob Agents; 2002 Sep; 20(3):186-95. PubMed ID: 12385697
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
    Soussy CJ, Nguyen J, Goldstein F, Dabernat H, Andremont A, Leclercq R, Drugeon H, Cavallo P, Chardon H, Etienne J, Rio Y, Courvalin P.
    Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
    [Abstract] [Full Text] [Related]

  • 6. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
    Nightingale CH.
    Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R.
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [Abstract] [Full Text] [Related]

  • 8. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT, Counts C, Lody C, Carter O, Dodson S, Ojha N.
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
    Tiengrim S, Phiboonbanakit D, Thunyaharn S, Tantisiriwat W, Santiwatanakul S, Susaengrat W, Srisurat N, Malithong A, Srisangchan P, Thamlikitkul V.
    J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S6-17. PubMed ID: 22574524
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
    Barry AL, Fuchs PC, Brown SD.
    Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):305-9. PubMed ID: 10385024
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria.
    Andrews JM, Ashby JP, Jevons GM, Wise R.
    J Antimicrob Chemother; 1999 Dec; 44(6):819-22. PubMed ID: 10590284
    [Abstract] [Full Text] [Related]

  • 15. [National multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens. Spanish Study Group on Moxifloxacin].
    Loza E, Morosini M, Negri MC, Almaraz F, Cantón R, Baquero F.
    Rev Esp Quimioter; 2000 Mar; 13(1):37-43. PubMed ID: 10855023
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Diagn Microbiol Infect Dis; 2001 Mar; 40(1-2):51-7. PubMed ID: 11448564
    [Abstract] [Full Text] [Related]

  • 18. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison.
    Duggirala A, Joseph J, Sharma S, Nutheti R, Garg P, Das T.
    Indian J Ophthalmol; 2007 Mar; 55(1):15-9. PubMed ID: 17189881
    [Abstract] [Full Text] [Related]

  • 19. National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents.
    Liebowitz LD, Slabbert M, Huisamen A.
    J Clin Pathol; 2003 May; 56(5):344-7. PubMed ID: 12719453
    [Abstract] [Full Text] [Related]

  • 20. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.
    Jones ME, Staples AM, Critchley I, Thornsberry C, Heinze P, Engler HD, Sahm DF.
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2645-52. PubMed ID: 10991838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.